2. Signaling Pathways
  3. Immunology/Inflammation
  4. Fc Receptor (FcR)
  5. Fc Receptor (FcR) Antagonist

Fc Receptor (FcR) Antagonist

Fc Receptor (FcR) Antagonists (5):

Cat. No. Product Name Effect Purity
  • HY-P991225
    BI-1206
    		Antagonist
    BI-1206 is a recombinant and antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). BI-1206 can block CD20 internalization induced by Rituximab (HY-P9913) itself or combined with others including Ibrutinib (HY-10997), Venetoclax (HY-15531), and CHOP. BI-1206 can enhance or recover the activity of Rituximab or other anti-CD20 monoclonal antibodies. BI-1206 has cytolytic activity against malignant B cells. BI-1206 can be studied for cancer research such as mantle cell lymphoma (MCL).
  • HY-179609
    C201-0243
    		Antagonist
    C201-0243 is a FcRn antagonist. C201-0243 exhibits antagonistic activity against IgG-FcRn binding with an IC50 of 3.439 nM. C201-0243 can be used in the research of IgG-mediated autoimmune diseases.
  • HY-P992211
    Anti-CD32b/FCGR2B Antibody (2B6)
    		Antagonist
    Anti-CD32b/FCGR2B Antibody (2B6) is a human monoclonal antibody targeting CD32B. Anti-CD32b/FCGR2B Antibody (2B6) can be used for research on B-cell lymphoma.
  • HY-P991476
    MDX-220
    		Antagonist
    MDX-220 is a human monoclonal antibody (mAb) targeting FcRn. MDX-220 has anti-tumor activity.
  • HY-P991582
    BI-1607
    		Antagonist
    BI-1607 is a humanized monoclonal antibody targeting CD32b/FcγRIIB. BI-1607 has an antagonistic function capable of blocking the inhibitory function of FcγRIIB on immune effector cells. BI-1607 has a significant cytolytic activity against malignant B cells and antitumor activity against HER2-positive solid tumors including advanced gastric cancer (GC) with combination with Trastuzumab (HY-P9907).